These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18653245)

  • 21. [Cyclosporin A in the treatment of Eaton-Lambert myasthenic syndrome].
    Yuste Ara JR; Beloqui Ruiz O; Artieda Gonzalez-Granda J; Herrero Santos JI; De la Peña Fernandez A; Prieto Valtueña J
    An Med Interna; 1996 Jan; 13(1):25-6. PubMed ID: 8679819
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neurogenic electromyographic activity in a patient with non-paraneoplasic Lambert-Eaton syndrome].
    Lapergue B; Lefaucheur JP; Bourahoui A; Nordine T; Hosseini H; Créange A
    Rev Neurol (Paris); 2007 Dec; 163(12):1227-31. PubMed ID: 18355470
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SFEMG improvement with remission in the cancer-associated Lambert-Eaton myasthenic syndrome.
    Oh SJ
    Muscle Nerve; 1989 Oct; 12(10):844-8. PubMed ID: 2558313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoimmune disorders of neuromuscular transmission.
    Mahadeva B; Phillips LH; Juel VC
    Semin Neurol; 2008 Apr; 28(2):212-27. PubMed ID: 18351523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients.
    Titulaer MJ; Wirtz PW; Kuks JB; Schelhaas HJ; van der Kooi AJ; Faber CG; van der Pol WL; de Visser M; Sillevis Smitt PA; Verschuuren JJ
    J Neuroimmunol; 2008 Sep; 201-202():153-8. PubMed ID: 18644631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lambert-Eaton myasthenic syndrome].
    Motomura M; Fukuda T
    Brain Nerve; 2011 Jul; 63(7):745-54. PubMed ID: 21747145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes.
    Lennon VA; Kryzer TJ; Griesmann GE; O'Suilleabhain PE; Windebank AJ; Woppmann A; Miljanich GP; Lambert EH
    N Engl J Med; 1995 Jun; 332(22):1467-74. PubMed ID: 7739683
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist.
    Tarr TB; Lacomis D; Reddel SW; Liang M; Valdomir G; Frasso M; Wipf P; Meriney SD
    J Physiol; 2014 Aug; 592(16):3687-96. PubMed ID: 25015919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct evolution of calcium channel antibody types in Lambert-Eaton myasthenic syndrome.
    Martin-Moutot N; De Haro L; Seagar M
    J Neuroimmunol; 2008 Jun; 197(1):47-53. PubMed ID: 18474401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lambert-Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders.
    Argov Z; Shapira Y; Averbuch-Heller L; Wirguin I
    Muscle Nerve; 1995 Jul; 18(7):715-9. PubMed ID: 7783761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association of systemic lupus erythematosus and Lambert-Eaton myasthenic syndrome.
    Deodhar A; Norden J; So Y; Bennett R
    J Rheumatol; 1996 Jul; 23(7):1292-4. PubMed ID: 8823710
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebellar ataxia in non-paraneoplastic Lambert-Eaton myasthenic syndrome.
    Lorenzoni PJ; Scola RH; Lang B; Kay CS; Teive HA; Kowacs PA; Werneck LC
    J Neurol Sci; 2008 Jul; 270(1-2):194-6. PubMed ID: 18374949
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Editorial introduction: from the structure and functions of the neuromuscular junction to the diseases].
    Takamori M
    Brain Nerve; 2011 Jul; 63(7):635-40. PubMed ID: 21747132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction.
    Peers C; Johnston I; Lang B; Wray D
    Neurosci Lett; 1993 Apr; 153(1):45-8. PubMed ID: 8390031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anconeus muscle: a human muscle preparation suitable for in-vitro microelectrode studies.
    Maselli RA; Mass DP; Distad BJ; Richman DP
    Muscle Nerve; 1991 Dec; 14(12):1189-92. PubMed ID: 1662771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome.
    Fukuda T; Motomura M; Nakao Y; Shiraishi H; Yoshimura T; Iwanaga K; Tsujihata M; Eguchi K
    Ann Neurol; 2003 Jan; 53(1):21-8. PubMed ID: 12509844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome.
    Tarr TB; Wipf P; Meriney SD
    Mol Neurobiol; 2015 Aug; 52(1):456-63. PubMed ID: 25195700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolated dysphagia due to paraneoplastic myasthenic syndrome with anti-P/Q-type voltage-gated calcium-channel and anti-acetylcholine receptor antibodies.
    Fernandez-Torron R; Arcocha J; López-Picazo JM; Pardo J; Tamura MA; Carretero C; Pastor P
    Neuromuscul Disord; 2011 Feb; 21(2):126-8. PubMed ID: 21115345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
    Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
    Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome.
    Oh SJ; Hatanaka Y; Claussen GC; Sher E
    Muscle Nerve; 2007 Feb; 35(2):178-83. PubMed ID: 17058271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.